FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to an oral solid dosage form containing a therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt wherein an active ingredient makes more than 46 wt % of total weight of the oral dosage form. The oral dosage form is presented in the form of a tablet or a film-coated tablet, and contains an internal phase containting aliskiren or its pharmaceutically acceptable salt, an excipient, a binding agent and a disintegrant, and an external phase containing a disintegrant, an excipient, a glidant and a lubricant.
EFFECT: invention provides administration of the active ingredient aliskiren in the small oral dosage form; it is characterised by an acceptable disintegration time.
32 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
HALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2005 |
|
RU2384328C2 |
GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2009 |
|
RU2438661C2 |
GALENA COMPOSITION OF ALISKIREN AND HYDROCHLOROTHIAZIDE | 2007 |
|
RU2491058C2 |
GALENIC FORMULATIONS OF ALISKIREN | 2008 |
|
RU2483718C2 |
GALENICAL PREPARATIONS OF ORGANIC COMPOUNDS | 2010 |
|
RU2535090C2 |
ESCITALOPRAM AND HARD PHARMACETICAL COMPOSITION CONTAINING IT | 2007 |
|
RU2463039C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
NEW COMPOSITION | 2006 |
|
RU2821230C2 |
GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING COMBINATION OF VILDAGLIPTIN AND GLIQUIDONE | 2014 |
|
RU2585378C1 |
Authors
Dates
2013-04-27—Published
2011-08-25—Filed